Nuvalent, Inc. Common Stock Underwriting AgreementUnderwriting Agreement • November 1st, 2022 • Nuvalent, Inc. • Pharmaceutical preparations • New York
Nuvalent, Inc. a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters listed in Schedule 1 hereto (the “Underwriters”), for whom you are acting as representatives (the “Representatives”), an aggregate of 6,865,672 shares (the “Underwritten Shares”) of Class A common stock, par value $0.0001 per share (the “Common Stock”), of the Company, and, at the option of the Underwriters, up to an additional 1,029,850 shares of Common Stock of the Company (the “Option Shares”). The Underwritten Shares and the Option Shares are herein referred to as the “Shares.” The shares of Common Stock of the Company to be outstanding after giving effect to the sale of the Shares are referred to herein as the “Stock”. The Company hereby confirms its agreement with the several Underwriters concerning the purchase and sale of the Shares, as follows:
NUVALENT, INC. AMENDMENT NO. 1 TO SALES AGREEMENTSales Agreement • November 1st, 2022 • Nuvalent, Inc. • Pharmaceutical preparations • New York
